Post-marketing Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Observational
SUMMARY

Open-label, Uncontrolled, Multicenter Observational Study on the Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: No
View:

• Patients of any age with a documented diagnosis of congenital afibrinogenemia or hypofibrinogenemia expected to require on-demand in-hospital treatment for BEs with Fibryga

Locations
Other Locations
Germany
Medizinische Klinik 2 / Institut für Transfusionsmedizin Universitätsklinikum
Recruiting
Frankfurt
Gerinnungszentrum Hochtaunus
Recruiting
Hamburg
Contact Information
Primary
Gita Pezeshki, PhD
gita.pezeshki@octapharma.com
+12016041125
Backup
Sylvia Werner, MS
sylvia.werner@octapharma.com
+12016041149
Time Frame
Start Date: January 28, 2021
Estimated Completion Date: October 2027
Participants
Target number of participants: 25
Treatments
Fibryga
Fibryga (human plasma-derived fibrinogen concentrate)
Related Therapeutic Areas
Sponsors
Leads: Octapharma

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.